Summary
114.35 2.75(2.46%)10/11/2024
Vaxcyte Inc (PCVX)
Vaxcyte Inc (PCVX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.36 | 2.76 | 0.62 | 39.50 | 76.44 | 137.88 | 0.00 | 337.28 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 114.35 | |
| Open | 111.60 | |
| High | 114.61 | |
| Low | 111.16 | |
| Volume | 432,645 | |
| Change | 2.64 | |
| Change % | 2.36 | |
| Avg Volume (20 Days) | 506,990 | |
| Volume/Avg Volume (20 Days) Ratio | 0.85 | |
| 52 Week Range | 44.20 - 121.06 | |
| Price vs 52 Week High | -5.54% | |
| Price vs 52 Week Low | 158.71% | |
| Range | 2.46 | |
| Gap Up/Down | -0.11 | |
Fundamentals | ||
| Market Capitalization (Mln) | 13,574 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 50.50 | |
| Book Value | 5.8180 | |
| Earnings Per Share | -1.7910 | |
| EPS Estimate Current Quarter | -0.5500 | |
| EPS Estimate Next Quarter | -0.6300 | |
| EPS Estimate Current Year | -1.9400 | |
| EPS Estimate Next Year | -2.2500 | |
| Diluted EPS (TTM) | -1.7910 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.1538 | |
| Return on equity (TTM) | -0.2754 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.7507 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 52,785,100 | |
| Shares Float | 32,969,068 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 7.66 | |
| Institutions (%) | 88.59 | |
09/11 16:05 EST - globenewswire.com
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.
09/08 09:00 EST - seekingalpha.com
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They target invasive pneumococcal disease (IPD) with superior coverage compared to competitors. VAX-31's Phase 1/2 results demonstrated a favorable safety profile and strong immunogenicity, positioning it for Phase 3 trials by mid-2025.
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They target invasive pneumococcal disease (IPD) with superior coverage compared to competitors. VAX-31's Phase 1/2 results demonstrated a favorable safety profile and strong immunogenicity, positioning it for Phase 3 trials by mid-2025.
09/06 16:05 EST - globenewswire.com
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per share and pre-funded warrants to purchase 2,427,184 shares of common stock at a public offering price of $102.999 per pre-funded warrant. This includes the exercise in full by the underwriters of their option to purchase up to 1,893,203 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $1.5 billion, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 12,087,378 shares of common stock at a public offering price of $103.00 per share and pre-funded warrants to purchase 2,427,184 shares of common stock at a public offering price of $102.999 per pre-funded warrant. This includes the exercise in full by the underwriters of their option to purchase up to 1,893,203 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $1.5 billion, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
09/06 15:07 EST - seekingalpha.com
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% of IPD in U.S. adults, with Phase 3 trials expected to deliver top line data by mid-2026. Despite competition from Merck and GSK, Vaxcyte's innovative XpressCF platform offers a significant competitive edge in the growing PCV market.
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% of IPD in U.S. adults, with Phase 3 trials expected to deliver top line data by mid-2026. Despite competition from Merck and GSK, Vaxcyte's innovative XpressCF platform offers a significant competitive edge in the growing PCV market.
09/06 09:07 EST - marketwatch.com
Vaxcyte's stock dips after biotech completes $1.42 billion stock offering
Vaxcyte Inc.'s stock fell 3% early Friday, after the company completed a stock offering that is expected to generate $1.42 billion in proceeds.
Vaxcyte's stock dips after biotech completes $1.42 billion stock offering
Vaxcyte Inc.'s stock fell 3% early Friday, after the company completed a stock offering that is expected to generate $1.42 billion in proceeds.
09/05 01:22 EST - reuters.com
Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high
Vaxcyte , a clinical-stage vaccine developer, will raise $1.3 billion in gross proceeds by selling common stock and warrants, it said late on Wednesday, a day after its shares surged to a record high on promising results in a vaccine trial.
Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high
Vaxcyte , a clinical-stage vaccine developer, will raise $1.3 billion in gross proceeds by selling common stock and warrants, it said late on Wednesday, a day after its shares surged to a record high on promising results in a vaccine trial.
09/04 23:58 EST - globenewswire.com
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,893,203 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $103.00 per share, and the pre-funded warrants are being sold at a public offering price of $102.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $1.3 billion, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,893,203 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
09/04 11:56 EST - zacks.com
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.
09/03 16:01 EST - globenewswire.com
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public offering of $1.0 billion of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $150.0 million of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it has commenced an underwritten public offering of $1.0 billion of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional $150.0 million of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
09/03 14:10 EST - schaeffersresearch.com
Vaxcyte's Drug Update Pushes 2 Biotech Stocks Lower
Vaxcyte Inc (NASDAQ:PCVX) stock is surging today, after the biotechnology company announced positive study results for its drug designed to prevent invasive pneumococcal disease in adults aged 50 or older.
Vaxcyte's Drug Update Pushes 2 Biotech Stocks Lower
Vaxcyte Inc (NASDAQ:PCVX) stock is surging today, after the biotechnology company announced positive study results for its drug designed to prevent invasive pneumococcal disease in adults aged 50 or older.
09/03 10:48 EST - barrons.com
Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.
At the highest dose tested, Vaxcyte's shot elicited a stronger immune response against 18 of the 20 strains compared with Pfizer's.
Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.
At the highest dose tested, Vaxcyte's shot elicited a stronger immune response against 18 of the 20 strains compared with Pfizer's.
09/03 09:24 EST - reuters.com
Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine
Vaxcyte's shares surged more than 30% on Tuesday after the vaccine developer said its experimental pneumococcal vaccine showed promising results in an early-stage study, with a safety profile similar to rival Pfizer's shot.
Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine
Vaxcyte's shares surged more than 30% on Tuesday after the vaccine developer said its experimental pneumococcal vaccine showed promising results in an early-stage study, with a safety profile similar to rival Pfizer's shot.
09/03 09:07 EST - investors.com
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
Vaxcyte shares rocketed Tuesday after the biotech company delivered "stunning" test results for its pneumococcal vaccine.
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
Vaxcyte shares rocketed Tuesday after the biotech company delivered "stunning" test results for its pneumococcal vaccine.
09/03 08:51 EST - marketwatch.com
Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine
Vaxcyte Inc.'s stock soared 33% early Tuesday, after the vaccine maker reported positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine candidate in adults aged 50 and older.
Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine
Vaxcyte Inc.'s stock soared 33% early Tuesday, after the vaccine maker reported positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine candidate in adults aged 50 and older.
09/03 07:07 EST - globenewswire.com
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Criteria for All 31 Serotypes --
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Criteria for All 31 Serotypes --
09/02 18:40 EST - globenewswire.com
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older.
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older.
08/26 13:30 EST - prnewswire.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vaxcyte, Inc. (NASDAQ: PCVX)
NEW YORK , Aug. 26, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vaxcyte, Inc. (NASDAQ: PCVX) on behalf of the company's shareholders. The investigation seeks to determine whether Vaxcyte's directors breached their fiduciary duties in connection with recent corporate actions.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vaxcyte, Inc. (NASDAQ: PCVX)
NEW YORK , Aug. 26, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vaxcyte, Inc. (NASDAQ: PCVX) on behalf of the company's shareholders. The investigation seeks to determine whether Vaxcyte's directors breached their fiduciary duties in connection with recent corporate actions.
07/31 10:56 EST - zacks.com
Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
The consensus price target hints at a 25.2% upside potential for Vaxcyte (PCVX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?
The consensus price target hints at a 25.2% upside potential for Vaxcyte (PCVX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
07/29 13:00 EST - zacks.com
Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice
Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice
Does Vaxcyte, Inc. (PCVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
07/02 08:30 EST - globenewswire.com
Vaxcyte Appoints John Furey to Board of Directors
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors.
Vaxcyte Appoints John Furey to Board of Directors
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors.